Oncogenic determinants of the immune response in acute myeloid leukaemia

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/2003575

Funding Status
Status not available

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

There is an urgent need to develop new therapies for patients with AML. We have shown that the body's own immune system can target certain types of AML. We will determine how these types of AML change to escape control from the immune system and how this can be reversed to re-engage the anti-AML immune response. Using patient samples, we will determine how the anti-AML immune response changes during the course of standard therapy in order to best combine it with immune-targeted therapies.

Funded Activity Details

Start Date: 01-01-2020

End Date: End date not available

Funding Scheme: Ideas Grants

Funding Amount: $588,144.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

acute myeloid leukaemia (aml) | cancer immunology | cancer immunotherapy | mouse models

Related Links